Asynchronous onset of clinical disease in BSE-infected macaques.
This discrepancy was assumed to be attributable to the so-called species barrier, defined as the hindrance of an infectious agent to change its natural host. Upon crossing the species barrier, prion diseases often show a low attack rate in conjunction with a high variability in the preclinical incubation time. Thus, the consumption of BSE-contaminated products may have led either to a restricted infection or to a prolonged asymptomatic phase in some exposed persons. Therefore, concerns have been raised that asymptomatic carriers of vCJD might exist, posing a risk for unintentional human-to-human transmission.
First indications that transmission of BSE to primates may lead to variances in the preclinical incubation times were obtained by inoculating cynomolgus macaques with cattle-derived BSE material (4-6), even though in those studies not more than 3 animals were used. We have now used a group of 6 macaques that were infected with BSE at a comparable age and kept under identical and controlled experimental conditions.
Six captive-bred female cynomolgus macaques (Macaca fascicularis, purchased from the Centre de Recherche en Primatologie, Mauritius) were inoculated intracerebrally with 1 dose of 50 mg brain homogenate (10% wt/vol) derived from 11 BSE-infected cattle. Animal experimentation was performed in accordance with section 8 of the German Animal Protection Law in compliance with Directive 86/609/EEC. Macaques were housed in a social group, and behavioral changes were assessed on a daily basis by experienced animal care takers.
After inoculation, all 6 macaques remained healthy and asymptomatic for >30 months (Table). At 931 days postinfection, 1 animal showed indications of slight coordination disorders. Within a few days, afferent ataxia developed, and when the animal was separated from the others animals, she apparently became tame. After 2 weeks, the animal showed severe dysmetria of the extremities without obvious myoclonia. Dementia was apparent but could not be diagnosed by objective measures. For ethical reasons, the animal was euthanized 17 days after disease onset. Within the next 14 weeks, 3 more animals became symptomatic. After appearance of neurologic symptoms (ataxia, tremors), the affected animals were occasionally separated from the group when symptoms became more severe or attacks from asymptomatic animals occurred. The disease course in these animals was comparable to that of the first animal, but the progression was slower (91-103 days).
Two of the 6 animals remained asymptomatic for [approximately equal to] 1 additional year. Although daily monitoring was facilitated by the fact that only 2 macaques remained and that the caretakers were more experienced to recognize minor changes in behavior, symptoms were first detected 1,340 and 1,398 days postinfection, respectively. Clinical signs were similar to those observed in the previous 4 animals. The symptomatic periods before euthanasia for these macaques lasted 103 and 143 days, respectively (Table). Direct comparison revealed that the difference between the short (931-1,025 days) and the long (1,340-1,398 days) preclinical incubation time was statistically significant (Figure 1, log-rank [Mantel-Cox] test, p<0.05).
Test results of brain samples from all animals were positive for macaque-adapted BSE by Western blot analysis. In brief, brain tissue from each animal was homogenized and subjected to proteinase K (PK) treatment for 1 h at 37[degrees]C. Samples were separated on acrylamide gels and transferred to nitrocellulose membranes. Macaque-adapted BSE ([PrP.sup.Sc]) was detected by using the monoclonal anti-PrP antibody 11C6. PK-resistant PrP was detected in all 6 macaques, confirming that BSE was transmitted to the animals.
The individual glycopattern and band migration of macaque-adapted [PrP.sup.Sc] was compared with human sporadic CJD (sCJD) type 1, sCJD type 2, and vCJD. PK-resistant PrP from BSE-infected macaques co-migrated with type 2 sCJD and was clearly distinguishable from type 1 sCJD (Figure 2). The glycosylation pattern of macaque-adapted BSE was comparable with vCJD (6,7), which is characterized by an overrepresentation of diglycosylated [PrP.sup.Sc] (8,9). Using 11C6 antibody (10), we detected a slightly decreased signal of the diglycosylated [PrP.sup.Sc] isoform for sCJD, vCJD, and macaque-adapted BSE. We assume that this effect is related to a reduced affinity of the diglycosylated isoform to 11C6 that otherwise shows high sensitivity to macaque-adapted [PrP.sup.Sc]. Nevertheless, direct comparison showed a higher amount of the diglysosylated [PrP.sup.Sc] isoform in vCJD and macaque-adapted BSE than sCJD, which was also shown with a different monoclonal antibody, 3F4. This finding confirms that BSE transmission to macaques is comparable with, and can be used as a model for, human vCJD infection.
Several susceptibility studies using nonhuman primates as a model for human prion diseases hint to heterogeneity of the preclinical incubation period upon crossing the species barrier (5,11,12). However, because of the low number of no more than 3 animals, this variability was not always evident (4). Therefore, there was an urgent need to determine whether the transmission of BSE to humans is likely to lead to a similar diversity.
Our study using 6 cynomolgus macaques shows that the transmission of BSE to primates led to a significantly prolonged asymptomatic phase in 2 animals. Disease onset is influenced by several factors (13). Our study design enabled us to exclude that the route of transmission influenced the disease progression because the infectious agent was injected into the same brain region of each animal. Also, a limited infectious dose cannot be responsible, as shown by the attack rate of 100%. In addition, endogenous factors, such as age, the MM genotype at codon 129 (Table), and housing conditions, were comparable for all macaques.
Thus, we conclude that the variable asymptomatic phase is most likely influenced by the infectious agent (14) or the genomic diversity of the macaques (13). The animals in our study were not inbred. Therefore, differences in the genomic background may have influenced the time of disease onset. In contrast, the PrPSc migration patterns of the animals give no indications for different types or strains that evolved from the mixed BSE inoculum. However, further studies will have to verify this.
Nevertheless, during the BSE epidemics, the human population with its natural genomic diversity was also exposed to a nonhomogenous prion source. Therefore, our study closely mimics the human situation. Our results imply that a prolonged asymptomatic phase can be expected for vCJD. In light of the transmissibility of vCJD through blood transfusions (15), our findings emphasize the need for continued attention to the risks of secondary human-to-human transmission.
We thank J.P. Deslys for providing vCJD material.
This study was supported by European Union grant QLK1 CT-2002-01096 and BMH4-CT-98-6029.
Dr Montag is a microbiologist at the Department of Molecular and Cell Physiology at the Hannover Medical School. Her primary research interests are the molecular mechanisms of disease pathology, including prion disorders and inherited cardiac diseases.
(1.) Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, Groth DF, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell. 1983;35:349-58. http://dx.doi. org/10.1016/0092-8674(83)90168-X
(2.) Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:921-5. http://dx.doi.org/10.1016/S0140-6736(96)91412-9
(3.) Mackay GA, Knight RS, Ironside JW. The molecular epidemiology of variant CJD. Int J Mol Epidemiol Genet. 2011;2:217-27.
(4.) Lasmezas CI, Deslys JP, Demaimay R, Adjou KT, Lamoury F, Dormont D, et al. BSE transmission to macaques. Nature. 1996;381:743-4. http://dx.doi.org/10.1038/381743a0
(5.) Ono F, Terao K, Tase N, Hiyaoka A, Ohyama A, Tezuka Y, et al. Experimental transmission of bovine spongiform encephalopathy (BSE) to cynomolgus macaques, a non-human primate. Jpn J Infect Dis. 2011;64:50-4.
(6.) Lasmezas CI, Comoy E, Hawkins S, Herzog C, Mouthon F, Konold T, et al. Risk of oral infection with bovine spongiform encephalopathy agent in primates. Lancet. 2005;365:781-3.
(7.) Comoy EE, Casalone C, Lescoutra-Etchegaray N, Zanusso G, Freire S, Marce D, et al. Atypical BSE (BASE) transmitted from asymptomatic aging cattle to a primate. PLoS ONE. 2008;3:e3017. http://dx.doi.org/10.1371/journal.pone.0003017
(8.) Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39:767-78. http://dx.doi.org/10.1002/ana.410390613
(9.) Parchi P, Capellari S, Chen SG, Petersen RB, Gambetti P, Kopp N, et al. Typing prion isoforms. Nature. 1997;386:232-4. http://dx.doi. org/10.1038/386232a0
(10.) Krasemann S, Groschup MH, Harmeyer S, Hunsmann G, Bodemer W. Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Mol Med. 1996;2:725-34.
(11.) Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science. 1977;197:943-60. http://dx.doi.org/10.1126/ science.142303
(12.) Herzog C, Sales N, Etchegaray N, Charbonnier A, Freire S, Dormont D, et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet. 2004;363:422-8. http://dx.doi.org/10.1016/ S0140-6736(04)15487-1
(13.) Iyegbe CO, Abiola OO, Towlson C, Powell JF, Whatley SA. Evidence for varied aetiologies regulating the transmission of prion disease: implications for understanding the heritable basis of prion incubation times. PLoS ONE. 2010;5:e14186. http://dx.doi. org/10.1371/journal.pone.0014186
(14.) Parchi P, Cescatti M, Notari S, Schulz-Schaeffer WJ, Capellari S, Giese A, et al. Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain. 2010;133:3030-42. http://dx.doi.org/10.1093/brain/ awq234
(15.) Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417-21. http:// dx.doi.org/10.1016/S0140-6736(04)15486-X
Judith Montag,  Walter Schulz-Schaeffer, Annette Schrod, Gerhard Hunsmann, and Dirk Motzkus
 Current affiliation: Hannover Medical School, Hannover, Germany.
Author affiliations: German Primate Center, Gbttingen, Germany (J. Montag, A. Schrod, G. Hunsmann, D. Motzkus); and University of Gbttingen, Gbttingen (W. Schulz-Schaeffer)
Address for correspondence: Dirk Motzkus, German Primate Center, Kellnerweg 4, D-37077 Gottingen, Germany; email: firstname.lastname@example.org
Table. Incubation periods of cynomolgus macaques infected intracerebrally with 50 mg brain homogenate from bovine spongiform encephalopathy-infected cattle * Animal Haplotype at First clinical Duration of clinical codon 129 signs, dpi phase, dpi A1 M/M 931 17 A2 M/M 1,398 103 A3 M/M 946 91 A4 M/M 1,025 94 A5 M/M 1,340 143 A6 M/M 946 103 * dpi, days postinfection.
|Printer friendly Cite/link Email Feedback|
|Author:||Montag, Judith; Schulz-Schaeffer, Walter; Schrod, Annette; Hunsmann, Gerhard; Motzkus, Dirk|
|Publication:||Emerging Infectious Diseases|
|Date:||Jul 1, 2013|
|Previous Article:||Ciprofloxacin-resistant Campylobacter spp. in retail chicken, Western Canada.|
|Next Article:||Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009.|